Isradipine: Posthoc analysis

Isradipine: Posthoc analysis
# # # # Last year the results of the large STEADY-PD study were published. The investigators behind the Phase III clinical trial reported that the experimental treatment being tested had no effect on the progression of Parkinson’s in recently diagnosed individuals. The treatment being evaluated was a calcium channel blocker called isradipine – it is used for ... read more
Source: The Science of Parkinson’s diseasePublished on 2021-03-08By Simon